Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCPyV T-antigen vaccine
- Development stage
- Unknown
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
MCPyV T-antigen vaccine refers to a class of therapeutic cancer vaccines designed to target the Merkel cell polyomavirus (MCPyV) T-antigen oncoproteins, specifically the Large T-antigen (LT) and Small T-antigen (ST). These oncoproteins are constitutively expressed in approximately 80% of Merkel cell carcinoma (MCC) cases (virus-positive MCC) and are essential for tumor cell survival and oncogenesis, making them ideal tumor-specific antigens. Various vaccine platforms, including plasmid DNA (such as ITI-3000), mRNA, and peptide-based formulations, are being developed by academic institutions and biotechnology companies (such as Immunomic Therapeutics, Dana-Farber Cancer Institute, and the University of Virginia) to elicit robust CD4+ and CD8+ T-cell immune responses against these viral antigens to treat or prevent recurrence of virus-positive Merkel cell carcinoma.
- Other names
- MCPyV T-Ag vaccineMCPyV T-antigen-targeting vaccineMerkel cell polyomavirus T-Ag vaccineMerkel cell polyomavirus T-antigen vaccine
02
Targets
MHC I (MHC class I})MHC II (Major histocompatibility complex class II receptor)LTag (Polyomavirus large T antigen)MCPyV LT/sT (Merkel cell polyomavirus tumor antigens)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on MCPyV T-antigen vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCPyV T-antigen vaccine.